Zacks Investment Research
04 Nov 2025, 23:11 UTC · 46w ago
Verdict
Headline takes no side. We score MIRM +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Mirum Pharmaceuticals reported quarterly earnings of $0.05 per share, beating the consensus estimate of a $0.10 loss.
So whatA significant earnings beat (surprise of 150%) and a swing from loss to profit typically drive positive short-term price action.
More positive than 93% of claims this week
Mirum Pharmaceuticals reported quarterly revenues of $133.01 million, surpassing consensus estimates by 0.85% and increasing from $90.38 million year-over-year.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 79% of claims this week
The company has surpassed consensus EPS estimates three times and revenue estimates four times over the last four quarters.
So whatA consistent track record of beating estimates builds investor confidence in management's guidance and operational execution.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported a significant earnings beat, positive revenue growth, and a substantial year-to-date stock price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
+23.9%
Price agrees with the score
$87.96 vs $70.97 close before publication (Nov 4) · not market-adjusted
MIRM chart →
